A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
Status:
Recruiting
Trial end date:
2022-11-02
Target enrollment:
Participant gender:
Summary
SHP655 is a medicine used to treat sickle cell disease (SCD). The main aim of the study is to
measure the safety and tolerability of SHP655 in SCD participants.
Study participants will receive SHP655 or placebo on Day 1. Their SCD will be treated by
their doctor according to their doctor's usual clinical practice.
During the study, participants will be asked to follow-up on 13 days following SHP655 or
placebo administration for safety assessment. Maximum duration of participation is expected
to be about 2 months